PolarityBio Gains FDA Priority Review for SkinTE in DFUs
SALT LAKE CITY, Utah — September 15, 2026 PolarityBio announced that the U.S. Food and Drug Administration (FDA) has...
RMAT
Advertisement
Tenaya Therapeutics Gains RMAT Designation for TN-401
SOUTH SAN FRANCISCO, Calif. — September 14, 2026 Tenaya Therapeutics, Inc. announced that the U.S. Food and Drug Administration...
Artiva Biotherapeutics Advances AlloNK Toward Phase 3 in RA
SAN DIEGO, California — September 8, 2026 Artiva Biotherapeutics, Inc. announced planned clinical data disclosures and development milestones for...
Fate Therapeutics Advances FT819 in Lupus Nephritis
San Diego, California — August 14, 2026 Fate Therapeutics, Inc. has initiated the potentially registrational RECLAIM-LN Phase 2 clinical...
PTC Therapeutics to Acquire ST-920 Fabry Gene Therapy Program
Warren, New Jersey, August 12, 2026 PTC Therapeutics announced that it was selected as the winning bidder to acquire...
Advertisements
Pacira BioSciences Publishes Two-Year Phase 1 PCRX-201 Knee OA Data
BRISBANE, Calif., August 6, 2026 Pacira BioSciences announced the publication of positive two-year Phase 1 clinical trial results for...
Opus Genetics Completes Enrollment in OPGx-LCA5 Phase 3 Trial
RESEARCH TRIANGLE PARK, N.C., Aug. 3, 2026 Opus Genetics, Inc. has completed patient enrollment in its registrational Phase 3...
Opus Genetics Secures FDA Alignment for Phase 3 Trial
RESEARCH TRIANGLE PARK, N.C., July 6, 2026 Opus Genetics announced that the U.S. Food and Drug Administration (FDA) has...
Mesoblast Receives FDA BLA Filing Number for Rexlemestrocel-L
New York, USA & Melbourne, Australia, July 1, 2026 Mesoblast Limited announced that the U.S. Food and Drug Administration...
Opus Genetics Enters FDA RDEP Program for OPGx-LCA5
RESEARCH TRIANGLE PARK, N.C. – May 4, 2026 Opus Genetics Inc. has announced that its investigational gene therapy OPGx-LCA5...
Advertisement
